loader

Longeveron Inc.

NASDAQ:LGVN
1 min read

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome , a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024

Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS).

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES